Advanced Search
SUN Jianhua, JI Zhonghe, YU Yang, WU Haitao, LI Yan. Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 282-286. DOI: 10.3971/j.issn.1000-8578.2016.04.009
Citation: SUN Jianhua, JI Zhonghe, YU Yang, WU Haitao, LI Yan. Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 282-286. DOI: 10.3971/j.issn.1000-8578.2016.04.009

Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer

More Information
  • Received Date: June 22, 2015
  • Revised Date: November 26, 2015
  • Objective To evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) on patients with peritoneal carcinomatosis (PC) from advanced/ recurrent epithelial ovarian cancer (EOC). Methods We included 46 patients with advanced EOC (FIGO stage Ⅲc/Ⅳ, n=16, Group A) and recurrent EOC with PC (n=30, Group B) treated by CRS+HIPEC procedures. The primary endpoint was overall survival (OS) from the first treatment to disease-related death. The secondary endpoints were safety profiles. Results The median OS was 74.0 months (95%CI: 8.5-139.5) in Group A vs. 57.5 months (95%CI: 29.8-85.2) in Group B (P=0.68). The median OS for patients with PCI≤20 vs. PCI>20 were 76.6 months (95%CI: 56.5-96.7) vs. 38.5 months (95%CI: 24.2-52.8) (P=0.01). The median OS for patients with CC0-1 vs. CC2-3 were 79.5 months (95%CI: 64.8-94.2) vs. 24.3 months (95%CI: 13.9-34.7) (P=0.00). In the recurrent group, the median OS were 65.3 months (95%CI: 42.6-88.9) for platinum-sensitive patients vs. 20.0 months (95%CI: 14.5-23.5) for platinum resistant patients (P=0.05). There was no perioperative death. Postoperative adverse events occurred in five patients. Multivariate analysis revealed that CC0-1 and chemotherapy ≥ six cycles were the independent factors for OS improvement. Conclusion For patients with PC from advanced/recurrent EOC, CRS plus HIPEC could improve the OS with acceptable safety profiles, particularly for advanced EOC PC patients.
  • [1]
    Hennessy BT, Coleman RL, Markman M. Ovarian cancer[J]. Lancet, 2009, 374(9698): 1371-82.
    [2]
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer[J]. N Engl J Med, 1996, 33 4(1): 1-6.
    [3]
    Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21 (17): 3194-200.
    [4]
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20 (5): 1248-59.
    [5]
    van Driel WJ, Lok CA, Verwaal V, et al. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer[J]. Curr Treat Options Oncol, 2015, 16(4): 14.
    [6]
    Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment[J]. Expert Opin Pharmacother, 2014, 15(5): 623-36.
    [7]
    Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends[J]. Eur J Surg Oncol, 2010, 36(7): 599-603.
    [8]
    Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia[J]. Ann Surg Oncol, 2010, 17(6): 1710-2.
    [9]
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. J Clin Oncol, 20 12, 30(20): 2449-56.
    [10]
    Huang CQ, Yang XJ, Yu Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase Ⅱ study from a Chinese center[J]. PLoS One, 2014, 9(9): e108509.
    [11]
    Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 20 11, 18(6): 1575-81.
    [12]
    Li Y, Zhou YF, Liang H, et al. Expert consensus on the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis[J]. Zhongguo Zhong Liu Lin Chuang, 2015, 42(4): 198-206. [李雁, 周云峰, 梁 寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专 家共识[J]. 中国肿瘤临床, 2015, 42(4): 198-206.]
    [13]
    Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer[J]. Cancer Chemother Pharmacol, 19 99, 43 Suppl: S15-25.
    [14]
    Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome[J]. Eur J Surg Oncol, 2001, 27 (3): 239-43.
    [15]
    Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer[J]. Semin Oncol, 2007, 34(2 Suppl 2): S1-15.
    [16]
    Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer[J]. J Surg Oncol, 2010, 102(6): 663-70.
    [17]
    Ansaloni L, Agnoletti V, Amadori A, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2012, 22(5): 778-85.
    [18]
    Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer[J]. Ann Surg Oncol, 20 12, 19(7): 2352-9.
    [19]
    Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study[J]. Ann Surg Oncol, 2015, 22(5): 15 70-5.
    [20]
    Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results[J]. J Cancer Res Clin Oncol, 2009, 13 5(12): 1637-45.
    [21]
    Cascales Campos P, Gil J, Parrilla P. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer[J]. Eur J Surg Oncol, 2014, 40 (8): 970-5.
    [22]
    Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients[J]. Eur J Surg Oncol, 2013, 39(12): 14 35-43.
    [23]
    Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients[J]. Ann Surg Oncol, 2012, 19 (13): 4052-8.
  • Related Articles

    [1]CAO Wenjing, WANG Yulin, ZHAI Yuqing, ZHANG Zongliang, YUAN Jiangshui, SONG Weiqing. Expression and Clinical Significance of MIS18BP1 in Bladder Cancer Tissues[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 163-168. DOI: 10.3971/j.issn.1000-8578.2024.23.1041
    [2]ZHANG Yuanyuan, FANG Zhaoqin, LIANG Chao. Screening of Genes Involved in Hepatoma Cells SMMC-7721 Stress Response Induced by Different Stressors[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 463-467. DOI: 10.3971/j.issn.1000-8578.2016.06.006
    [3]Pei Feng, Zhu Yi. Clinical Significance of Cytokeratin18 Fragments in Diagnosis of Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(04): 439-441. DOI: 10.3971/j.issn.1000-8578.2012.04.018
    [4]YANG Guang-min, LI Shou-qing, MA Yin-fu, WEI Bing-bing, SHI Yang, TAN Yan. Anti-tumor Immunotherapy Effect of Co-expression Genetic Vaccine MAGE-1/IL-18[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 294-297. DOI: 10.3971/j.issn.1000-8578.2010.03.014
    [5]YANG Sheng, LU Hui-shan, CHEN Xiang-qi, LIN Ting-yan, LI Zhi-ying, KANG Ming-qiang. Effect of IL-18 on Growth and Apoptosis of Lewis Lung Cancer Xenografts in C57BL/6 Mice[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 563-565. DOI: 10.3971/j.issn.1000-8578.2009.07.007
    [6]ZHAO Hong-xia, WANG Yan-kui, LUO Bing, YIN Guang-jie. Influence of HPV18E6 Small Interfering RNA on p21,VEGF,Bax and Bcl-2 Genes in HeLa Cells[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 261-264. DOI: 10.3971/j.issn.1000-8578.2009.04.001
    [7]YANG Qin, CHEN Hong-lei, LIU Ming-qiu, FANG Zhong. PCR-SSCP Analysis of FADD Gene Mutation in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 162-164. DOI: 10.3971/j.issn.1000-8578.442
    [8]GAO Yan-e, YANG Hui-ping, ZHANG Ju, GUO Jin-zhu, LIU Ning-xia, YAN Xiao-jun. Cloning and Sequencing of Human Papillomavirus Type 18 L1 Gene from Cervical Cancer Tissue[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 159-161. DOI: 10.3971/j.issn.1000-8578.441
    [9]LI Ji-mei, LI Chun-hai, WANG Qin-qin, et al, . Detect ion of MUC1 and GST-P Gene by means of RT-PCR in Axillary Lymph Nodes Taken from Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 351-353. DOI: 10.3971/j.issn.1000-8578.1357
    [10]Luo YuanHui, . The Point Mutation of Ras and p53 Genes in Paraffin-embedded Gastric Cancer Tissues by PCR-RFLP Analysis[J]. Cancer Research on Prevention and Treatment, 1995, 22(2): 68-71.

Catalog

    Article views (1697) PDF downloads (688) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return